Pharmafile Logo

New report now available: Integrating ‘patient first’ into medicine development

- PMLiVE

A new report has just been published by Cuttsy+Cuttsy that collates all the current best thinking in the ‘patient first’ space, distilling it into a practical and actionable road map for your future clinical trial progress.  

Jon Hume, Commercial Director at Cuttsy+Cuttsy says that the report “takes a forward-thinking approach, touching upon the advancing adoption of patient-centricity at an organisational level yet aiming a sharp focus on what can still be done, or optimised, to secure the future success of clinical trials.” 

Get your copy here.

 

About Cuttsy+Cuttsy 

Cuttsy+Cuttsy are the original patient communications agency specialising in clinical trial engagement. As a trusted clinical trial and healthcare communications partner to the pharmaceutical industry since 2011, they’ve supported over 110,000 trial participants, across all major therapy areas, in more than 40 countries.   

This content was provided by Cuttsy + Cuttsy

Company Details

 Latest Content from  Cuttsy + Cuttsy 

Invited, but not equipped: patient involvement needs more than an open door

Explore how pharma can help patients and patient organisations prepare for meaningful involvement in EU HTA without shaping their contribution.

The outcomes are already chosen. So when can patients really shape them?

Explore why involving patients early in Joint Scientific Consultations is critical to shaping the outcomes measured in clinical trials.

Long-term clinical trial engagement is a behavioural challenge – not just an informational one

Explore why long-term clinical trial engagement is a behavioural challenge, showing how proactive support from site teams can help participants stay connected, confident and committed throughout a study.

Patients are telling the truth — just not to you

Patients are often most honest outside the clinic—revealing vital insights that can help clinical trial teams build trust, improve participation and collect better data.

When what matters to patients is hard to measure

Patient-relevant outcomes sit at the heart of the EU HTA reforms, but ensuring they reflect lived experience requires you to look beyond what traditional clinical endpoints measure.

Permission to pause: making treatment breaks part of the cancer care conversation

Exploring how empathetic, patient-centred communication can make planned treatment breaks easier to discuss as part of cancer care.

A seat at the table: what the EU HTA reforms really ask of patient involvement

The EU HTA reforms give patients a formal role in assessing new medicines, but meaningful involvement requires more than simply offering them a seat at the table.

Why faster trials make participant understanding more important than ever

As clinical trials accelerate, clear, accessible consent is essential to help participants understand, engage with and remain in a study.

Older trial participants reject bad design, not technology

Older trial participants aren’t rejecting digital technology — they’re rejecting poorly designed, inaccessible experiences that make participation harder.

5 key takeaways from the Patient Centricity and Engagement Conference

Key takeaways from the Patient Centricity and Engagement conference, exploring how trust, inclusion and meaningful partnership can help turn patient engagement from intention into action.